JP2019504003A5 - - Google Patents

Download PDF

Info

Publication number
JP2019504003A5
JP2019504003A5 JP2018530566A JP2018530566A JP2019504003A5 JP 2019504003 A5 JP2019504003 A5 JP 2019504003A5 JP 2018530566 A JP2018530566 A JP 2018530566A JP 2018530566 A JP2018530566 A JP 2018530566A JP 2019504003 A5 JP2019504003 A5 JP 2019504003A5
Authority
JP
Japan
Prior art keywords
raav
composition
composition according
human subject
genome copies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018530566A
Other languages
English (en)
Japanese (ja)
Other versions
JP7328760B2 (ja
JP2019504003A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/065984 external-priority patent/WO2017100682A1/en
Publication of JP2019504003A publication Critical patent/JP2019504003A/ja
Publication of JP2019504003A5 publication Critical patent/JP2019504003A5/ja
Priority to JP2022002190A priority Critical patent/JP2022050575A/ja
Application granted granted Critical
Publication of JP7328760B2 publication Critical patent/JP7328760B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018530566A 2015-12-11 2016-12-09 家族性高コレステロール血症を処置するための遺伝子治療 Active JP7328760B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022002190A JP2022050575A (ja) 2015-12-11 2022-01-11 家族性高コレステロール血症を処置するための遺伝子治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562266383P 2015-12-11 2015-12-11
US62/266,383 2015-12-11
US201562269440P 2015-12-18 2015-12-18
US62/269,440 2015-12-18
PCT/US2016/065984 WO2017100682A1 (en) 2015-12-11 2016-12-09 Gene therapy for treating familial hypercholesterolemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022002190A Division JP2022050575A (ja) 2015-12-11 2022-01-11 家族性高コレステロール血症を処置するための遺伝子治療

Publications (3)

Publication Number Publication Date
JP2019504003A JP2019504003A (ja) 2019-02-14
JP2019504003A5 true JP2019504003A5 (cg-RX-API-DMAC7.html) 2020-01-23
JP7328760B2 JP7328760B2 (ja) 2023-08-17

Family

ID=57794341

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018530566A Active JP7328760B2 (ja) 2015-12-11 2016-12-09 家族性高コレステロール血症を処置するための遺伝子治療
JP2022002190A Pending JP2022050575A (ja) 2015-12-11 2022-01-11 家族性高コレステロール血症を処置するための遺伝子治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022002190A Pending JP2022050575A (ja) 2015-12-11 2022-01-11 家族性高コレステロール血症を処置するための遺伝子治療

Country Status (14)

Country Link
US (2) US10889832B2 (cg-RX-API-DMAC7.html)
EP (2) EP4085934A1 (cg-RX-API-DMAC7.html)
JP (2) JP7328760B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180113990A (cg-RX-API-DMAC7.html)
CN (2) CN109121421B (cg-RX-API-DMAC7.html)
AU (2) AU2016366560A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018011687A2 (cg-RX-API-DMAC7.html)
CA (1) CA3008142A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018007165A2 (cg-RX-API-DMAC7.html)
ES (1) ES2921450T3 (cg-RX-API-DMAC7.html)
IL (2) IL259850B2 (cg-RX-API-DMAC7.html)
MA (1) MA43570A (cg-RX-API-DMAC7.html)
MX (1) MX2018007080A (cg-RX-API-DMAC7.html)
WO (1) WO2017100682A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11555059B2 (en) 2014-04-25 2023-01-17 The Trustees Of The University Of Pennsylvania LDLR variants and their use in compositions for reducing cholesterol levels
EP4085934A1 (en) 2015-12-11 2022-11-09 The Trustees of The University of Pennsylvania Gene therapy for treating familial hypercholesterolemia
AU2017299779B2 (en) 2016-07-21 2021-12-02 Spark Therapeutics, Inc. Scalable high recovery methods for producing high yield recombinant adeno-associated viral (rAAV) vector and recombinant adeno-associated viral (rAAV) vectors produced thereby
WO2018022511A1 (en) 2016-07-25 2018-02-01 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
JP2020510648A (ja) 2017-02-20 2020-04-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 家族性高コレステロール血症を処置するための遺伝子治療
EA202091352A1 (ru) * 2017-11-30 2020-08-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Генотерапия мукополисахаридоза iiib
JP2022518354A (ja) * 2018-12-20 2022-03-15 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 家族性高コレステロール血症を治療するための遺伝子療法
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
AU2020392243A1 (en) * 2019-11-28 2022-06-16 Regenxbio Inc. Microdystrophin gene therapy constructs and uses thereof
WO2021222653A1 (en) * 2020-04-29 2021-11-04 Saliogen Therapeutics, Inc. Compositions and methods for treatment of familial hypercholesterolemia and elevated low-density lipoprotein cholesterol
MX2023008826A (es) 2021-02-01 2023-09-15 Regenxbio Inc Terapia génica para lipofuscinosis neuronal ceroidea.
CN117887723A (zh) * 2024-01-08 2024-04-16 苏州诺洁贝生物技术有限公司 密码子优化的ldlr基因及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
EP1007637B1 (en) 1997-04-14 2004-06-30 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant aav product
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US6596535B1 (en) 1999-08-09 2003-07-22 Targeted Genetics Corporation Metabolically activated recombinant viral vectors and methods for the preparation and use
AU6814901A (en) 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
CN1780910A (zh) * 2003-01-28 2006-05-31 拉塞有限公司 对与家族性高胆固醇血症有关的分离的低密度脂蛋白受体(ldl-r)的基因序列中的突变进行检测的方法和装置
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
US7769466B2 (en) 2006-02-24 2010-08-03 Kenergy, Inc. Class-E radio frequency amplifier for use with an implantable medical device
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
KR101010352B1 (ko) 2008-05-30 2011-01-25 삼성중공업 주식회사 전력 제어 장치 및 방법
WO2010088560A1 (en) * 2009-01-29 2010-08-05 University Of California, San Francisco Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders
WO2011020118A1 (en) * 2009-08-14 2011-02-17 Theramind Research, Llc Methods and compositions for treatment of tuberous sclerosis complex
EP2529020B1 (en) * 2010-01-28 2018-04-25 The Children's Hospital of Philadelphia A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
WO2011126808A2 (en) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
KR20140041747A (ko) 2011-06-20 2014-04-04 제넨테크, 인크. Pcsk9-결합 폴리펩티드 및 사용 방법
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
EP3795581A3 (en) 2011-08-24 2021-06-09 The Board of Trustees of the Leland Stanford Junior University New avv capsid proteins for nucleic acid transfer
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
BR112014020325A2 (pt) * 2012-02-17 2017-08-08 Childrens Hospital Philadelphia composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos
WO2014124282A1 (en) 2013-02-08 2014-08-14 The Trustees Of The University Of Pennsylvania Enhanced aav-mediated gene transfer for retinal therapies
AU2014216160B2 (en) * 2013-02-15 2017-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services AAV8 retinoschisin expression vector for treating X-linked retinoschisis
US8980864B2 (en) * 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
BR112015021036A2 (pt) * 2013-03-15 2017-10-10 Univ Pennsylvania composições e métodos para tratar mps1
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
US11555059B2 (en) 2014-04-25 2023-01-17 The Trustees Of The University Of Pennsylvania LDLR variants and their use in compositions for reducing cholesterol levels
CR20160519A (es) * 2014-05-13 2017-01-27 The Trustees Of The Univ Of Pennysylvania Composiciones que comprenden avv que expresa constructos de anticuerpos duales y sus usos
EP4085934A1 (en) 2015-12-11 2022-11-09 The Trustees of The University of Pennsylvania Gene therapy for treating familial hypercholesterolemia
US11015174B2 (en) 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV8
JP2020510648A (ja) 2017-02-20 2020-04-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 家族性高コレステロール血症を処置するための遺伝子治療

Similar Documents

Publication Publication Date Title
JP2020510648A5 (cg-RX-API-DMAC7.html)
Raina et al. An update on LDL apheresis for nephrotic syndrome
Xun et al. Metformin inhibits hepatitis B virus protein production and replication in human hepatoma cells
Pei et al. Efficient capsid antigen presentation from adeno-associated virus empty virions in vivo
JP2020537637A5 (cg-RX-API-DMAC7.html)
RU2020126034A (ru) Векторы фактора fviii на основе аденоассоциированных вирусов, соответствующие вирусные частицы и содержащие их терапевтические композиции
Meng et al. Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance
JP2020514286A5 (cg-RX-API-DMAC7.html)
RU2022102472A (ru) Фиксированные комбинации и составы, содержащие etc-1002 и эзетимиб, и способы лечения или уменьшения риска развития сердечно-сосудистого заболевания
CN111225677A (zh) 单采血液分离方法和用途
Descamps et al. Two key challenges for effective adenovirus-mediated liver gene therapy: innate immune responses and hepatocyte-specific transduction
EP3134113A1 (en) Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
Hollinger et al. Viral vector mediated gene therapies
Notarte et al. Infusion reactions to adeno‐associated virus (AAV)‐based gene therapy: Mechanisms, diagnostics, treatment and review of the literature
JP2018502112A5 (cg-RX-API-DMAC7.html)
JP2024041907A (ja) Cd4ムテインおよびその使用方法
Yamaguti-Hayakawa et al. Gene therapy: paving new roads in the treatment of hemophilia
JP2003501114A (ja) 治療用ウイルス免疫原性剤投与の有効性を増強する方法
Kumar et al. AAV viral vectors as therapeutic interventions for inherited or non-inherited cardiac disorders: current aspects and future prospects
King et al. High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity
JP5665899B2 (ja) 癌の処置のための粘液腫ウイルス変異体
JP2021500880A5 (cg-RX-API-DMAC7.html)
Wang et al. Viral vectors in neurodegenerative diseases: immune responses and therapeutic applications
Parajuli et al. Immune Toxicities in AAV Gene Therapy: Overview for Clinicians
Jiang et al. Adenovirus infection results in alterations of insulin signaling and glucose homeostasis